Multiple Sclerosis
What this study is
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Study details
- Sponsor
- CorEvitas
- Conditions
- Multiple Sclerosis
- Enrolling
- 1,000 people
- Starts
- 2017-08-10
- Est. completion
- 2100-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Has a diagnosis of MS at the time of enrollment.
- Age 18 years or older at the time of enrollment.
- Willing to provide Personal Information.
- Initiating (prescribed or starting) an Eligible Medication for the treatment of MS at the enrollment visit.
You can't join if
- Is participating or planning to participate in a double-blind randomized trial for an MS drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openCorEvitas, LLC
Waltham, Massachusetts, United States
Study team
Sponsor
CorEvitas
Study ID CorEvitas-MS-700
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.